Here we find that AIM2 upregulation refers to a favorable progression-free survival rate in cancer patients receiving nivolumab, pembrolizumab, atezolizumab or ipilimumab monotherapy even though its upregulation was not significant for predicting the responsiveness of cancer patients who received nivolumab or atezolizumab monotherapy in ROC plot analysis. Here, AIM2 is linked to cancer.